Whether delivered through injection or oral therapy, a treatment that regrows cartilage would reshape the landscape of arthritis care, reduce healthcare costs, and spare countless ... Mar 02
The blood-brain barrier, often overlooked in early dementia research, may hold the key to delaying or mitigating cognitive decline.... Feb 24
Ageing may remain inevitable, but the pace at which it unfolds is no longer entirely beyond our influence.... Jan 23
The story of a 19-year-old diagnosed with a disease associated with old age is a reminder that the human brain still holds many ... Jan 08
The story of tryptophan, once reduced to a sleep aid myth, now appears far more consequential and reminds us that small molecules, guided by the ... Jan 07
If untreated sleep apnea turns out to be a factor that increases vulnerability to Parkinson’s disease, then awareness and early intervention could change outcomes ... Nov 28
As the world continues exploring the remarkable connection between microbes and the brain, the hope is that one day, patients will face a future where ... Nov 26
By taking proactive steps to reduce obesity, manage blood pressure, and adopt a heart-healthy lifestyle, individuals can protect not only their hearts but also ... Dec 06
As researchers dive deeper into the role of long genes in aging, new avenues for therapeutic intervention may emerge... Mar 28
The discovery of nasal immunotherapy with anti-CD3 as a potential treatment for Alzheimer's disease represents a ray of hope for the millions of ... Sep 15
Latest Pharma news... Feb 23
Latest Pharma Update... Jul 30
Much steeper declines in cognitive skills and routine daily functioning already evident then ... Jul 08
Polaryx Therapeutics, today announced that it has received from the U.S. Food and Drug Administration (FDA) both Rare Pediatric Disease and Orphan Drug Designations ... Dec 18
The acquisition will establish a new modality for drug discovery and development at Lilly ... Dec 15
Athira Pharma, today announced that patient dosing has begun in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with ... Dec 02
Polaryx Therapeutics has received from the US FDA both Rare Pediatric Disease and Orphan Drug designations for the treatment of GM2 gangliosidosis with PLX-300... Nov 25
... Oct 30
... Oct 27
Eli Lilly successfully develop and commercialize new medicines resulting from the acquisition... Oct 16
Global strategic partnership with ABL Bio for the co-development of a SARS-CoV-2 neutralizing antibody... Sep 15
... Feb 07
GNT Pharma has successfully completed a Phase III clinical trial for crisdesalazine, a new drug for treating canine cognitive dysfunction syndrome or Alzheimer’s disease. ... Jan 16
Decision Drives Anti-Aging Market Emerging Studies Reveal Ergothioneine consumption is Correlated to Reducing Mild Cognitive Impairment... Aug 21
-Advertisements-
.jpeg)
Tuesday, October 06, 2026
.jpeg)
.jpeg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
